Better Phase II Could Allow For More Single-Trial Approvals, Temple Says
Executive Summary
Increased emphasis on Phase II trials could improve drug development and potentially allow more drug approvals based on a single Phase III clinical trial, Center for Drug Evaluation & Research Associate Director for Medical Policy Robert Temple, MD, suggested Jan. 15
You may also be interested in...
Single Phase III Trial Plus Confirmatory Data May Aid NDAs - UCSF's Sheiner
A single, well-controlled efficacy trial supported by confirmatory evidence may establish pharmacological causality better than traditional trial replication, Lewis Sheiner, MD, University of California-San Francisco, told a Drug Information Association meeting Jan. 22.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials